Search
Relaxin receptor 1
go.drugbank.com/bio_entities/BE0019700TargetHumansReceptor for relaxins. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. Binding of the ligand may also activate a tyrosine kinase pathway that inhibits the activ...
Synonyms: Leucine-rich repeat-containing G protein-coupled receptor 7Amorolfine
go.drugbank.com/drugs/DB09056ApprovedWithdrawnAmorolfine 5% nail lacquer in once or twice weekly applications is 60-71% effective in treating toenail onychomycosis; complete cure rates three months after stopping treatment (after six months of treatment … It is not approved for the treatment of onychomycosis in the United States or Canada.
Celiprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnIn 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome. … Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome.
Synonyms: RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylureaKappadione
go.drugbank.com/drugs/DB09332ApprovedIt has been found to have carcinogenic potential in mammalian cells as well as cytotoxic properties [L1544]. … Studies involving the active metabolite of this formulation, menadione, showed oocyte toxicity in a study of mice [L1544].
Hexylcaine
go.drugbank.com/drugs/DB00473ApprovedWithdrawnHexylcaine has been discontinued in the US market. … Patients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.
Tocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. … Two biosimilar versions of tocilizumab have since been approved by the FDA: tocilizumab-bavi, in September 2023,[L48385] and Tyenne® (tocilizumab), in June 2024.
Products: ACTEMRA (162 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE), ACTEMRA 162MG/0.9ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGEUnexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells
go.drugbank.com/drugs/DB28348Approved[L54146] Zemcelpro was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation following myeloablative conditioning … in adult patients for whom a suitable donor is not available.
Acetyl hexapeptide-3
go.drugbank.com/drugs/DB11709InvestigationalArgireline has been used in trials studying the treatment of wrinkles.
Mixtures: Laser Rejuvenation restoring damage skinNuclear factor of activated T-cells, cytoplasmic 1
go.drugbank.com/bio_entities/BE0004878TargetHumansPlays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2 or IL-4 gene transcription. Also controls gene expression in embryonic cardiac cells. Could regulate not only the activation a...
Synonyms: NFAT transcription complex cytosolic component